Lipella Pharmaceuticals Inc. (LIPO)
OTCMKTS · Delayed Price · Currency is USD
0.7100
+0.0090 (1.28%)
Aug 1, 2025, 2:53 PM EDT

Intercept Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202020
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2020
0.520.540.450.180.260.96
Upgrade
Revenue Growth (YoY)
8.88%19.29%144.15%-28.99%-73.03%38.42%
Upgrade
Cost of Revenue
3.763.613.042.551.460.98
Upgrade
Gross Profit
-3.24-3.08-2.59-2.36-1.2-0.01
Upgrade
Selling, General & Admin
1.9522.160.230.720.04
Upgrade
Operating Expenses
1.9522.160.230.720.04
Upgrade
Operating Income
-5.19-5.08-4.75-2.59-1.92-0.06
Upgrade
Interest Expense
---0.01-0.01-0.01-0.01
Upgrade
Interest & Investment Income
0.060.060.14000
Upgrade
Other Non Operating Income (Expenses)
----00-
Upgrade
EBT Excluding Unusual Items
-5.13-5.02-4.62-2.6-1.92-0.06
Upgrade
Other Unusual Items
----0.06-
Upgrade
Pretax Income
-5.13-5.02-4.62-2.6-1.87-0.06
Upgrade
Net Income
-5.13-5.02-4.62-2.6-1.87-0.06
Upgrade
Net Income to Common
-5.13-5.02-4.62-2.6-1.87-0.06
Upgrade
Shares Outstanding (Basic)
111100
Upgrade
Shares Outstanding (Diluted)
111100
Upgrade
Shares Change (YoY)
67.07%39.69%47.84%19.15%59.91%2.46%
Upgrade
EPS (Basic)
-3.84-4.79-6.16-5.12-4.38-0.23
Upgrade
EPS (Diluted)
-3.85-4.79-6.16-5.12-4.40-0.23
Upgrade
Free Cash Flow
-3.99-3.95-3.16-1.83-0.99-0.03
Upgrade
Free Cash Flow Per Share
-2.99-3.77-4.22-3.61-2.32-0.11
Upgrade
Gross Margin
------1.48%
Upgrade
Operating Margin
-998.47%-947.23%-1055.56%-1406.26%-738.71%-5.91%
Upgrade
Profit Margin
-986.98%-935.25%-1027.31%-1410.59%-719.30%-6.41%
Upgrade
Free Cash Flow Margin
-767.20%-736.59%-703.85%-994.35%-381.45%-2.97%
Upgrade
EBITDA
-5.19-5.08-4.74---
Upgrade
D&A For EBITDA
000---
Upgrade
EBIT
-5.19-5.08-4.75-2.59-1.92-0.06
Upgrade
EBIT Margin
------5.91%
Upgrade
Revenue as Reported
0.520.540.450.180.260.96
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.